Zydus, Formycon Partner to Bring Keytruda Biosimilar to US/Canada Market

• Zydus Lifesciences partnered with Germany's Formycon AG to commercialize FYB206, a biosimilar of Merck's Keytruda, in the US and Canada.
• This agreement marks Zydus' entry into the North American biosimilar market, focusing on an immunotherapy product.
• Formycon will develop, register, manufacture, and supply FYB206, while Zydus will handle its commercialization.
• The move capitalizes on Keytruda's US patent expiry in 2028, opening a multi-billion-dollar market for affordable oncology biosimilars.
• A Biologics License Application (BLA) filing with the USFDA for FYB206 is anticipated soon.

Why It Matters: New partnership promises affordable cancer treatment for US patients.